To identify signature targets associated with patient-specific cancer lesions based on tumor versus normal tissue differential protein and mRNA coexpression patterns for the purpose of synthesizing cancer-specific customized RNA interference knockdown therapeutics. Analysis of biopsied tissue involved two-dimensional difference in-gel electrophoresis (2D-DIGE) analysis coupled with MALDI-TOF/TOF mass spectrometry for proteomic assessment. Standard microarray techniques were utilized for mRNA analysis. Priority was assigned to overexpressed protein targets with co-overexpressed genes with a high likelihood of functional nodal centrality in the cancer network as defined by the interactive databases BIND, HPRD and ResNet. HPLC-grade small interfering RNA (siRNA) duplexes were utilized to assess knockdown of target proteins in expressive cell lines as measured by western blot. Seven patients with metastatic cancer underwent biopsy. One patient (RW001) had biopsies from two disease sites 10 months apart. Seven priority proteins were identified, one for each patient (RACK 1, Ras related nuclear protein, heat-shock 27 kDa protein 1, superoxide dismutase, enolase1, stathmin1 and cofilin1). Prioritized proteins in RW001 from the two disease sites over time were the same. We demonstrated 480% siRNA inhibition of RACK 1 and stathmin1 of inexpressive malignant cell lines with correlated cell kill. Identification of functionally relevant target gene fingerprints, unique to an individual's cancer, is feasible 'at the bedside' and can be utilized to synthesize siRNA knockdown therapeutics. Further animal safety testing followed by clinical study is recommended.
Introduction
Our understanding of the biomolecular basis of cancer has virtually exploded over the last 10 years. Developments in genetics, molecular biology and molecular pharmacology promise to alter dramatically strategies of cancer treatment. 1, 2 Clearly, previous therapeutic principles derived from cytotoxic based therapy now provide diminishing return with respect to patient benefit. 3 Targeted therapeutics, a 'new wave' of cancer treatment, are directed against amplified genes and/or overexpressed protein kinases in malignant cells. However, the presence of function redundancy in a robust, predominantly scale-free network such as cancer buffers the effect of any single gene/target modification on the malignant process, with rare exception (for example, CML). [4] [5] [6] The hierarchy of cancer scale-free networks does not have a threshold for stochastic single target-mediated network disruption insofar as random pathway component failure predominantly affects targets with low connectivity within the network, thereby having limited functional impact . 7 However, highly connected targets do allow for 'attack vulnerability'. 5, 7, 8 The disordered cancer circuitry can become, almost paradoxically, more highly dependent on a specific rewired pathway (that is, pathway addiction). 9 The disruption of pathways that produce robustness to certain insults are often associated with enhanced fragility to other perturbations thereby exposing an 'Achilles' heel' of cancer. 9 Therapeutic target identification based on the degree of connectivity of dynamic genomic-proteomic nodes (or hubs) in a patient-data-based network model, as opposed to targeting the more highly active metabolic pathways in rapidly proliferating cancer cells in accord with traditional chemotherapy principles, may be a more effective rationale for anti-tumor target prioritization. 4, 7, 10, 11 In such an approach, the most intriguing targets derived from a patient's differential genomic-proteomic profile will be those highly interconnected 'hub' genes, which control cancer cell competitive survival, metastagenicity and/or cancer stem-cell renewal. 7 , 10 We herein demonstrate that semi-quantitative molecular data proteomic [12] [13] [14] and genomic profiling [15] [16] [17] [18] derived by comparing malignant and non-malignant tissue from patients with progressive cancer can be analyzed in the context of global protein interaction networks to generate a prioritized list of potential protein and gene targets. Moreover, the differential overexpression of these putative targets in tumor versus normal tissue, supports an RNA interference knockdown strategy [19] [20] [21] [22] further justifying evaluation in the individual patient.
Materials and methods

Patient selection
Seven patients underwent normal and malignant tissue biopsy. One patient RW001 had a second biopsy of recurrent cancer from a different disease site 10 months after his initial biopsy. Tissue was immediately frozen in liquid nitrogen and further processed for microarray and protein analysis. Identifier, disease type, age and sex of the seven patients are as follows: RW001, melanoma, 72, male; JJ002, Lymphoma, 76, female; LSN003, breast cancer, 35, female; SK004, melanoma, 35, female; JAG005, non-small cell lung cancer, 58, male; DCL006, prostate cancer, 64 male and HW007, non small cell lung cancer, 54, male. Before surgery, an IRB-approved tissue harvest consent was obtained. Normal tissue adjacent to the biopsy site and normal skin were biopsied for comparative analysis. All patients had greater than 90% cancer cells in the malignant biopsy specimen analyzed. The samples were analyzed for differential and discriminatory genomic and proteomic expression.
RNA expansion and microarray RNA was extracted using PicoPure RNA Isolation kit (Arcturus Bioscience, Mountainview, CA). Quality of captured RNA was examined with Agilent 2100 Bioanalyzer using RNA 6000 Pico LabChip (Agilent Technologies, Palo Alto, CA). The remainder of the sample was split into two equal proportions for parallel RNA amplification and gene profile analysis. R 2 test was performed to provide an indicator for the reproducibility of duplicates. RNA is amplified before labeling. For RNA amplification, RiboAmp RNA amplification Kit (Arcturus Bioscience, Mountainview, CA) was used. Quality of the amplified RNA is examined with BioAnalyzer. Gene expression profile was established by bioinformatics analysis (Gene Spring 7.2 software). Hybridization and processing of GeneChip used the automated GeneChip Instrument System. Data acquisition, sample normalization and initial data analysis was performed with Affymetrix Microarray Suite (MAS) software. Probes with significant present cells (P-value o0.05) were selected following quantile normalization from bioconductor (www.bioconductor.org) to correct for systematic bias among samples. 23 The tumor sample and normal control were then analyzed in pairwise fashion to identify genes that are significantly upregulated in tumors.
Proteomics: 2D-DIGE/MS and data analysis Ten milligrams of human tumor tissues were lysed in 2-D lysis buffer containing 30 mM Tris-HCl (pH 8.8), 7M urea, 2M thiourea and 4% CHAPS. Cleared protein lysates were labeled with CyDye fluors (Cy2, Cy3 or Cy5) for 30 min at 01C. The reactions were terminated with the addition of lysine, and samples to be compared were mixed in an equal molar ratio. Destreak solution and rehydration buffer were added (100 ml each) before samples were loaded on a 13-cm IPG strip (pH 3-10 linear range, Amersham). After IEF was completed, the IPG strip was incubated with SDS-containing equilibration solutions and laid on top of a 9-12% gradient SDS gel (18 Â 16 cm, 1 mm thickness). Electrophoresis was carried out, then the gel was scanned using Typhoon Trio scanner (GE Healthcare/Amersham), and the images were analyzed using ImageQuant and DeCyder software. Protein spots of interest were excised and protein IDs were determined using MALDI-TOF/TOF mass spectrometry.
Tumor gene-expression profile analysis and RNAi target selection via protein interaction networks High-quality raw data from microarray and 2D-DIGE/ MS were analyzed with our network analysis system to identify potential RNAi targets. The list of targets were prioritized sequentially. (1) High cancer cell compared to low normal cell protein expression (X2-fold elevated ratio) was identified. (2) Highly expressed proteins were identified and functionally characterized for processes associated with oncogenesis, such as: angiogenesis, apoptosis, cell cycle, cell cycle gene, DNA repair, migration, proliferation, signaling, stem cell association and transcription activity through a known literature search. (3) Proteins consistent with cancer processes and elevated mRNA expression (41.5-fold) in tumor were weighted as higher priority. Additionally, presence of high cross-species DNA sequence conservation in identified proteins were maintained as higher priority. 24 This enabled us to narrow down the list of possible targets from 16 to 5 in the case RW. The remaining targets were then prioritized using information of protein-protein interactions. Thus, for each of the above targets that met these criteria, protein-protein interactions fulfilling gene ontology (GO) assignments 25 frequently assigned to known cancer causing genes (determined through an enrichment analysis of GO terms assigned to oncogenes cataloged in the Cancer Census). 26 were obtained from the human protein interaction databases of BIND, HPRD and ResNet. [27] [28] [29] The most highly connected proteins were chosen as targets for further analysis.
Design, synthesis of siRNAs For each selected RNAi target, we culled the literature and sought commercially available small interfering RNA (siRNA) from the Cancer Genome Anatomy Project's RNAi site of NCI (http://cgap.nci. nih.gov/RNAi) and from appropriate venters (www.ambion.com). Commercial siRNA sequences were available (synthetic predesigned protein-specific siRNA duplexes) of HPLC grade were purchased.
Test efficacy of siRNAs in vitro on cancer cell lines Selected siRNAs were tested on human cancer tissue culture cell lines HCT 116 Colon Cancer Cell Line (CCL247) and MDA-MB-231 Adenocarcinoma Breast (HTB26) from ATCC (Manassas, VA). For each selected RNAi target gene, we compared gene expression data compiled for NCI 60 cell lines to identify those cell lines that have similar abnormally high expression level of the targeted genes (http://cmap.nci.nih.gov/Profiles/ProfileQuery) (http://discover.nci.nih.gov). Each selected cell lines were tested for a group of identified target genes that are overexpressed. The cell lines were obtained from ATCC. We utilized the selected cell lines to validate siRNAs.
We first determined the RNAi activity for each siRNA on selected cell lines. The cells were transfected with each siRNA duplex at an effective dose range to determine the optimum dose for each target using the (siPORT NeoFX lipid based RNAi transfection kit from Ambion, Austin, TX). A control non-silencing siRNA duplex with scrambled sequence is used to determine target mRNA level in selected cell lines. A time course of knockdown was then determined.
We also determined each siRNA's ability to suppress tumor cell growth. Cell growth arrest of transfected cells at days 1, 2, 4, 7 and 10 post-infection, was tested by trypan blue exclusion method. Transfection efficiency was monitored with fluorescent oligonucleotides (Ambion, Austin, TX) to correct variation in transfection efficiency.
We harvested RNA and protein from transfected cells and subject the total RNA to microarray and 2D DIGE/ms with comparison of baseline at 24 and 72 h posttransfection times.
Immunohistochemical evaluation
Frozen tumor tissue cryosections and / or formalin fixed paraffin embedded sections were tested by immunohistochemical staining method for the cells expressing the selected proteins using selected primary antibodies from BD Biosciences (San Diego, CA) and Abcam (Cambridge, MA). Staining was carried out using Universal Quick kit from Vector Laboratories Vectastain (Burlingame, CA) and color development was by DAB (3, 3 0 -diaminobenzenidine) substrate for peroxidase (Vector Laboratories). Counter stain was by hematoxylin. Relevant IgG was used as a negative control.
Western blot analysis
Paired tissue sample total protein was tested by western blot for the selected protein expressions. Normal peripheral blood mononuclear cells, skin and on unaffected lymph node, were used as control. Total protein from cell lines expressing the selected proteins were extracted and tested by western blot analysis. Cell lines showing the expression of the selected proteins were transfected using siPORT NeoFX transfection agent (Ambion, Austin, TX) with silencer Pre-designed siRNA for the target gene, transfection reagent alone and a silencer negative control # 1 siRNA of 19 bp scrambled sequence with 3' dT overhangs (Ambion) for time periods of 24 h, 48 h, 4 days and 7 days. Total cell protein was extracted using CelLytic M (Sigma, Saint Louis, MO) supplemented with protease inhibitor cocktail (Sigma). The protein estimation was carried out using Coomassie (Bradford) Protein Assay Kit (Pierce, Rockford, IL). The proteins were Figure 2 ) and the five selected target proteins (Figure 3 ). On the basis of connectivity to known first order cancer growth molecules, we chose RACK1 as the highest priority protein target for RNAi validation. An additional six cancer patients underwent the same process as RW001. Primary targets of these patients were as follows: JJ002, Ras related nuclear protein; LSN003, superoxide dismutase; SK004, heat-shock 27 kDa protein 1; JAG005, enolase 1; DCL006, stathmin 1 and HW007, cofilin 1. These are demonstrated within the priority protein connectivity maps in Figure 3 . 
Immunohistochemical staining
Western blot
Antibodies to RACK1, and stathmin 1 were demonstrated in cancer cells lines (HCT 116, CCL-247, and MDA-MB-435S HTB-129) by western blot analysis. Expression of RACK1 in tumor and normal tissue by western blot analysis is shown in Figure 5a .
cDNA microarray Marked similarity of mRNA expression of malignant tissue 10 months apart from consistent with earlier described protein expression patterns was identified ( Figure 6 ). The ratio of mRNA expression in malignant and normal tissue of the top five targets is shown in Table 1 . Figure 5b ). A cell kill of 450% was correlated to RACK1 ( Figure 5c ) and stathmin 1 inhibition. Optimization of siRNA knockdown to demonstrate greater cell kill was not performed.
Discussion
Our study demonstrates consistent ability (7 of 7) to identify patient-unique overexpressed protein targets in biopsied cancer specimens without corresponding expression in normal tissue through a process involving genomic and proteomic assay, and network mapping. Proteins are the direct effectors of cellular behavior rather than their DNA and mRNA templates. Characterization of protein expression provides the most immediate assessment of cellular functional capacity. It is noteworthy that proteomics analysis of RW001 yielded protein candidates (syntenin) that have previously been associated with this tumor cell type [30] [31] [32] as well as others (shown in Table 1 ) that were previously ascribed to lung, liver, renal cell, bladder, prostate, gastric or breast cancers. Proteins assemble themselves into networks through a variety of protein-protein interactions. 56 The resolution of these coupling events and in silico prediction of outcome from the disruption of these events are likely to provide the functional basis for defining novel and, potentially effective targets for drug therapy. [57] [58] [59] [60] Pathogenic gene mutations, gene loss and gene duplication or amplification can result in defective, absent or overexpressed proteins. These proteins realign within the cellular protein network in a 'degenerative' pattern resulting in an oncopathologic hostile takeover. 61 The culling of unique tumor genetic features illustrate the appeal of our systematic approach for the development of personalized cancer therapeutics, especially when coupled with confirmatory functional analysis for individual candidate genes. Correlation of gene expression patterns with disease outcome (survival) has been demonstrated in a variety of cancers. [16] [17] [18] [62] [63] [64] However, gene transcript levels often show poor correlation with protein levels and they cannot predict post-translational modifications. For stathmin 1, TPI 1, RACK1 and syntenin identified in RW001, there was remarkable concurrence in the magnitude of upregulation at the mRNA and proteomic level, suggesting genetic defects at the transcription level. By using the criteria of (1) differential expression, (2) linkage to essential oncogenic processes and (3) high connectivity, it is feasible to reduce a finite number of overexpressed proteins in malignant tissue into a smaller subset of candidate of targets, for which potentially therapeutic siRNA or shRNA agents can be constructed. These products can then be used to enable a systemic loss- of-function analysis, to validate a complex of 'target gene targets' for trial investigation. It is envisioned that future RNAi-based gene therapy for cancer can be prescribed based on the integrated mRNA-proteomic expression profile of each individual's tumor. Preliminary comparisons between siRNA and shRNA indicate that shRNA induced knockdown is more durable and efficient than siRNA. 65, 66 and, furthermore, more amenable to a second layer of tumor specificity via tumor-targeted vector control thereby minimizing nonmalignant cell uptake and potential toxic effect to nontarget agents. [67] [68] [69] [70] [71] [72] Comparing patient-specific molecular profiles with known pathways and with networks derived from protein interaction databases provides a means for identifying oncotoxic targets. However, the majority of the data underlying our understanding of cancer and, especially, the characterization of cancer gene-protein-metabolic networks, are based on animal and cell line systems. network configurations. 58, 59, [73] [74] [75] [76] These approaches are data intensive and would require molecular profiling data in correlation with siRNA knockdown and tumor response from a large cohort of patients. The accumulation of data from patient tumors together with network inference technology provides a means to automated construction of probabilistic network models based on 'real-world' clinical data, enabling rapid discovery and characterization of oncogenic pathways in humans and timely response to individual patient needs. Although, in patient RW001 described in this paper, RACK1 tumor expression was proportionately elevated in comparison to both normal skin (site of origin) and lymph node (metastatic anatomic target site), whether the tissue of origin, the metastatic target site, or a standard common reference tissue should be used is still under evaluation. Another consideration is that clonal section and/or genetic instability can result in a quantifiable if not qualitative genomic/proteomic disparity producing intratumoral heterogeneity (that is, within the primary, between the primary and metastatic sites and between different metastatic sites). It is notable that in a recent analysis, intratumoral heterogeneity was low for the majority of tested probe sets. 77 One approach that we are exploring is whether circulating tumor cells (and/or bone marrow tumor cells) can provide a representative matrix of tumor bimolecular evolution to allow for a multiplex therapeutic moiety targeting an array of integrated processes in the tumor genomic-proteomic network. A combination of shRNA vectors targeting multiple cancer support pathways and multifunctional RNAi constructs are expected to optimize therapeutic potential. 78, 79 The time required to determine high-probability protein targets (3-6 weeks) and to manufacture and validate safety of an shRNA product (6 months) may limit the use of this technology in patients with rapidly progressive disease, but conservation of the priority protein targets in tumor samples as demonstrated from patient RW001 with samples harvested nearly 10 months apart suggest an opportunity for application in patients with earlier stage, slowly progressive disease or recurrent disease following a long-latent period.
We are currently pursuing development of shRNA nano particle delivery vehicles for each of the top priority targets identified in the seven patients tested.
